Loading…
NSRX
Nasus Pharma Ltd
NYSE American· Healthcare· Drug Manufacturers - General· CUSIP M7071P109
$4.100.00%Price as of Aug 29, 18:49 UTC · updated once a day, after the close
Key metrics
- Market cap
- $48.01M
- P/E
- —
- Forward P/E
- —
- P/B
- 4.4x
- Dividend yield
- —
- Payout
- —
- EPS
- -$1.13
- ROE
- -316.04%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- —
- 52-week high
- $9.50
- 52-week low
- $1.98
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -57.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| POCIPrecision Optics Corporation Inc | $4.40 | — | 2.4x | — | -29.62% | $48.16M |
| IBOImpact Biomedical Inc | $0.44 | 0.5x | 4.4x | — | 23.46% | $47.84M |
| GNTAGenenta Science S.p.A. | $1.00 | — | 0.9x | — | -38.03% | $48.22M |
| NEPHNephros Inc | $4.55 |
About the company
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
- 7
- Tel Aviv-Yafo, Israel
Company description provided by Yahoo Finance.